Thalamic Stimulation Promotes, While Mfb Stimulation Inhibits, Calcium Oscillatory Activity in the Rat Striatum

In vivo fiber-optic recording using ion-induced fluorescence
  • M. Duff Davis
Part of the Advances in Behavioral Biology book series (ABBI, volume 52)


Parkinson’s disease (PD) is a progressive disorder that involves a marked functional degradation of the extrapyramidal nigrostriatal dopamine system. Present, palliative-only therapeutic strategies include (1) replacement of lost dopamine tone, for example through L-DOPA treatment (Rinne, 1987; Shoulson, 2000) or fetal mesencephalic transplantation (Lindvall et al., 1994), (2) post-synaptic dopamine receptor activating drugs including pramipexole (Rinne, 1987), or bromocriptine (Shoulson, 2000) and (3) surgical ablation such as globus pallidotomy (Lang and Lozano, 1998), among others. More recently, either deep brain stimulation (DBS) or thalatotomy (Bejjani, 2000) may offer paradoxically similar beneficial outcomes for some PD patients. Though aggressive clinical trials are still ongoing, DBS seems to be particularly effective in attenuating drug-induced dyskinesias that often develop during prolonged L-DOPA treatment (Nutte, 2000), and this reliably enough that the procedure has just been endorsed for wider use by the U.S. Federal Drug Administration. As yet, the specific mechanism by which DBS offers relief is unresolved.


Deep Brain Stimulation Medial Forebrain Bundle Calcium Oscillation Medium Spiny Neuron Burst Firing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bejjani, B., L-Dopa-induced dyskenesia in Parkinson’s disease: is it reversible7Ann.Neurot.47, 655–658 (2000).Google Scholar
  2. Blanchet, P.J., Metman, L.V., Mouradian, M.M., and Chase, T.N., Acute pharmacologic blockade of dyskinesias in Parkinson’s disease, Mov. Disord. 11: 580–581 (1996).CrossRefGoogle Scholar
  3. Cepeda, C., Walsh, J.P., Hull, C.D., Howard, S.G., Buchwald, N.A., and Levine, M.S., Dye-coupling in the neostriatum of the rat: I. Modulation by dopamine-depleting lesionsSynapse4: 229–237 (1989).PubMedCrossRefGoogle Scholar
  4. Davis, M.D., Changes in striatal calcium signalling and neuronal firing following electrical stimulation of the rat thalamus, sub-thalamus and medial forebrain bundle as measured using ion-sensitive fluorescent probesSoc. Neurosc. Abstr.26:, p. 1287 (2000).Google Scholar
  5. Davis, M.D., and Schmidt, J.J., In vivo spectrometric calcium flux recordings of intrinsic caudate-putamen cells and transplanted IMR-32 neuroblastoma cells using miniature fiber optrodes in anesthetized and awake rats and monkeysJ. Neurosc. Methods99, 9–23 (2000).CrossRefGoogle Scholar
  6. Hu, X.-T., and Wang, R.Y., Comparison ofeffectsof D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study,J. Neurosc.8: 4340–4348 (1988).Google Scholar
  7. Koller, W., Pahwa, R., Busenbark, K., Hubble, J., Wilkinson, S., Lang, A., Tuite, P., Sime, E., Lazono, A., Hauser, R., Malapira, T., Smith, D., Tarsy, D., Miyawaki, E., Norregaard, T., Kormos, T., and Olanow, C.W., High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonien tremorAnn Neurol.49: 292–299 (1997).CrossRefGoogle Scholar
  8. Lang, A.P., and Lozano, A.E., Parkinson’s diseaseNewEngi. J. Med.339, 1044–1053 (1998).CrossRefGoogle Scholar
  9. Lindvall, O., Sawle, G., Widner, H., Rothwell, J.C., Bjorklund, A., Brooks, D., Brundin, P., Frackowiack, R.,Marsden, C.D., Odin, P., and Rehncrona, N., Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s diseaseAnn. Neurol.35, 172–180 (1994).PubMedCrossRefGoogle Scholar
  10. Nutt, J.G., Obeso, J.A., and Stocchi, F., Continuous dopamine-receptor stimulation in advanced Parkinson’s diseaseTrends Neurosci.23 (Suppl), S109–5115 (2000).PubMedCrossRefGoogle Scholar
  11. Odonnell, P., Grace, A.A., Cortical afferents modulate striatal gap junction permeability via nitric oxideNeurosci. 76: 1–5(1997).CrossRefGoogle Scholar
  12. Onn, S.-P., and Grace, A.A., Alterations in electrophysiological activity and dye coupling of striatal spiny an aspiny neurons in dopamine-denervated rat striatum recorded in vivoSynapse33: 1–15 (1999).PubMedCrossRefGoogle Scholar
  13. Papa, S.M., Boldry, R.C., and Engber, T.M., Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockadeBrain Research701: 13–18 (1995).PubMedCrossRefGoogle Scholar
  14. Papa, S.M., and Chase, T.N., Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys, Ann Neurol. 39: 574–578 (1996).PubMedCrossRefGoogle Scholar
  15. Paxinos, G., and Watson, C., The rat brain in stereotaxic coordinates, Academic Press, Orlando, FL (1996). Rinne, U.K., Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a S- year follow-upNeurology37, 826–828 (1987).CrossRefGoogle Scholar
  16. Shoulson, I., Pramipexole versus levodopa in early Parkinson’s disease: the randomized controlled CALM-PD trialMov. Disord.15 (Suppl. 3), S4 (2000).Google Scholar
  17. Wachtel, S.R., Hu, X.-T., Galloway, M.P., and White, F.J., D1 receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 agonists in nigrostriatal and mesoaccumbens dopamine systems, Synapse 4: 327–346 (1989).PubMedCrossRefGoogle Scholar
  18. Wilson, C.J., and Kawaguchi, Y., The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neuronsJ. Neurosci.16: 2397–2410 (1996).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • M. Duff Davis
    • 1
  1. 1.Department of CNS PharmacologyPfizer Global Research and DevelopmentAnn ArborUSA

Personalised recommendations